ALLIANCES AND COLLABORATIONS (Pfizer) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended							1 Months Ended	12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012 Eliquis [Member]	Dec. 31, 2012 Pfizer [Member] Eliquis [Member]	Dec. 31, 2011 Pfizer [Member] Eliquis [Member]	Dec. 31, 2010 Pfizer [Member] Eliquis [Member]	Feb. 28, 2013 Pfizer [Member] Eliquis [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 Pfizer [Member] Eliquis [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2011 Pfizer [Member] Eliquis [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2010 Pfizer [Member] Eliquis [Member] Upfront, milestone and other licensing payments [Member]
Alliances and Collaborations Statement [Line Items]
Percentage reimbursement of development costs from collaboration partner													60.00%
Total upfront, milestone and other licensing payments																	$ 654
Upfront licensing and milestone payments received																95	20	65	10
Potential additional development and regulatory milestone receipts																	230
Net Sales	4,191	3,736	4,443	5,251	5,454	5,345	5,434	5,011	17,621	21,244	19,484	2
Commercialization expense reimbursements to/(from) collaboration partner													(18)	(10)	(8)
Research and development reimbursements to/(from) collaboration partner													7	(65)	(190)
Amortization income - upfront, milestone and other licensing payments																	(37)	(33)	(31)
Deferred income	$ 4,849				$ 1,203				$ 4,849	$ 1,203							$ 397	$ 434